October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025
Read More
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in Rodent Models of Rheumatoid Arthritis
American College of Rheumatology (ACR) 2025
Read More
September 29, 2025
Safety, Pharmacokinetics and Pharmacodynamics of KT-621, an Oral STAT6 Degrader, in Healthy Adults
European Respiratory Society (ERS) 2025 Congress – Late Breaking Presentation
Healthy Volunteers
Read More
September 17, 2025
The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models
European Academy of Dermatology & Venereology (EADV) 2025
Atopic Dermatitis (AD)
Asthma
Read More
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
Healthy Volunteers
Read More
May 19, 2025
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically
American Thoracic Society (ATS) 2025
Read More
May 17, 2025
Revolutionizing Immunology: Oral Medicines with Biologics-like Activity
American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
April 17, 2025
Cell Chemical Biology: CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
Kwiatkowski, et al.
Read More
March 8, 2025
Clinical and Translational Science: Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults
Agarwal, et al.
Read More
December 9, 2024
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
American Society of Hematology (ASH) 2024
Other
Read More